First Mature Estimation of Median OS for Selpercatinib in Patients with RET Fusion-Positive NSCLC By Ogkologos - March 12, 2025 877 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from final efficacy and safety analyses from the LIBRETTO-001 study Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR Adjuvant Multiagent Chemotherapy Regimens Associated with OS Benefit Following Resection of... March 11, 2025 Coming Full Circle on Cancer and Extrachromosomal DNA May 10, 2023 What to Know When Searching for Cancer Information Online: An Expert... December 7, 2021 Coping With Cancer Recurrence: My Perspective As Both a Patient and... January 24, 2023 Load more HOT NEWS EMA Recommends to Extend the Indications for Tislelizumab Pazopanib Shows Promise for Children, Adults with Soft Tissue Sarcomas Zucchini everywhere Targeted Therapy for Claudin-18.2 and Combined PD-1 and TIGIT Immunotherapy for...
